

UOB Investment Insights

Quick Note

22 May 2020

Potential De-Listing of Chinese Companies in the US

- The US has threatened to de-list Chinese companies from their stock exchanges.
- If passed, there will likely be a transition period for companies to comply with the new rules. This allows time for companies and investors to react.
- US investors make up a relatively small portion of Chinese equity investors.
- There are alternate ways to invest in Chinese equities, such as through Hong Kong or the A-shares market.

The US Threatens To De-List Chinese Companies

- On Wednesday (20 May 2020), the US Senate passed the Holding Foreign Companies Accountable Act. This proposed bill can potentially lead to the suspension or de-listing of foreign companies listed in the US that are unable to comply with audit requirements.
- Although the bill is not explicitly targeting China, it is specific to Chinese companies because China's regulations prohibit foreign regulators like the US' Securities and Exchange Commission (SEC) from examining the audit papers for overseas listed Chinese companies.
- The move is likely to be politically motivated and is one of the responses from the Trump administration to penalise China for the ongoing COVID-19 impact to the US. It could also be part of a wider US effort to undermine the rise of China.
- **Next steps:** The bill has to be passed by the House before it can be sent to President Trump to be signed into law. At the time of writing, it is unclear how long the process will take.

Quick Facts About US-Listed Chinese Companies


- Currently 233 Chinese companies are listed as American Depository Receipts (ADRs) in the US¹.
- ADRs
 - are denominated in US dollars, with the underlying security held by a US financial institution overseas.
 - can be listed on the New York Stock Exchange (NYSE), American Stock Exchange (AMEX), the NASDAQ, or sold over-the-counter (OTC).
 - allow investors to access foreign companies through US stock exchanges.
- Total listed market cap of US\$ 1.03 trillion, which makes up 3.3% of US equity market cap and 8% of all-China market cap (Figure 1).

¹ Goldman Sachs Global Investment Research, 21 May 2020

UOB Investment Insights

Quick Note


Figure 1: Chinese ADRs currently represent 3.3% of total US market cap



Source: Wind, FactSet, Goldman Sachs Global Investment Research.

- Chinese ADRs make up 6% of daily US trading volume (US\$ 8.1 billion).
- US investors are estimated² to hold US\$ 350 billion worth (roughly 1/3) of Chinese ADRs, which makes up approximately 50% of their Chinese equity holdings (Figure 2).

Figure 2: Approx. 50% of US investors' holdings in Chinese equities are in ADRs.



Source: Wind, CEIC, US Department of Treasury, Bloomberg, Goldman Sachs Global Investment Research.

Note: The US holdings of China A-shares and HK-listed stocks are estimated based on data disclosed by the US Treasury. The US ownership of US-listed Chinese stocks is calculated as the total US holdings divided by the total listed market based on stock-level data from Bloomberg.

² Goldman Sachs Global Investment Research, as at 21 May 2020

UOB Investment Insights

Quick Note

What Are The Possible Outcomes?

- If the Act is passed into law, there may be some **short term negative impact** on the Chinese ADRs, especially the smaller cap stocks, given their lower liquidity.
- Chinese companies will be likely given a **3-year window** to allow US regulators to examine their financial statements. This 3-year window may allow for potential negotiation between the regulators and the companies on the level and stringency of compliance.
- Non-compliance will most likely result in **forced de-listing**, which could result in price movements. However, the potential 3-year transition period will provide sufficient time for investors to react, thereby minimizing the negative impact.
- Alternatively, companies can choose to **voluntarily de-list** from the US and re-list elsewhere. In this scenario, the most likely market to benefit will be Hong Kong. Many of these companies are already dual-listed in Hong Kong, thus reducing any possible disruption.

What should investors do?

- **Do not rush to react.** While initial market sentiment to this news may be negative, there will likely be a 3-year transition period. This allows time for investors to react to any developments.
- **Invest in China as a long-term Megatrend.** The US' actions should not derail the long-term drivers for China's growth: rising domestic consumption and its growing leadership in technology developments and deployment. While it may deter some fund flows into Chinese equities, most investors (retail or institutional) are still able to access Chinese equities via Hong Kong or the A-shares market either directly or through a fund.
- If you are invested in Chinese equities through:
 - **a mutual fund or unit trust**, the fund manager will likely make the necessary changes to their portfolios ahead of any deadlines to minimise disruption. Both Hong Kong and the A-shares market are easily accessible to fund managers. The fund managers we have spoken to have indicated there should not be any long-term impact to their portfolios. There should not be any action required from you.
 - **a structured product**, there may be a possibility that one or more underlying companies may voluntarily de-list in the US and re-list elsewhere in the interim. We will contact you should this happen to provide further details and possible courses of action from the note issuer. In the meantime, the structured product will continue as intended. You should also consider this possibility when you invest in structured products in future.
 - **direct equities**, you may want to consider gradually shifting to shares of the same company listed elsewhere where available and within a reasonable timeframe, when the price differentials and currency differences may be in your favour.
- Please speak to your UOB Advisor to determine whether there are any actions you need to take in your investment portfolio.

**All data are sourced from Bloomberg unless otherwise stated.*



RIGHT BY YOU

IMPORTANT NOTICE AND DISCLAIMERS:

The information contained in this publication is given on a general basis without obligation and is strictly for information purposes only. This publication is not intended to be, and should not be regarded as, an offer, recommendation, solicitation or advice to buy or sell any investment or insurance product and shall not be transmitted, disclosed, copied or relied upon by any person for whatever purpose. Any description of investment or insurance products, if any, is qualified in its entirety by the terms and conditions of the investment or insurance product and if applicable, the prospectus or constituting document of the investment or insurance product. Nothing in this publication constitutes accounting, legal, regulatory, tax, financial or other advice. If in doubt, you should consult your own professional advisers about issues discussed herein.

The information contained in this publication, including any data, projections and underlying assumptions, are based on certain assumptions, management forecasts and analysis of known information and reflects prevailing conditions as of the date of the publication, all of which are subject to change at any time without notice. Although every reasonable care has been taken to ensure the accuracy and objectivity of the information contained in this publication, United Overseas Bank Limited ("UOB") and its employees make no representation or warranty of any kind, express, implied or statutory, and shall not be responsible or liable for its completeness or accuracy. As such, UOB and its employees accept no liability for any error, inaccuracy, omission or any consequence or any loss/damage howsoever suffered by any person, arising from any reliance by any person on the views expressed or information contained in this publication.

Any opinions, projections and other forward looking statements contained in this publication regarding future events or performance of, including but not limited to, countries, markets or companies are not necessarily indicative of, and may differ from actual events or results. The information herein has no regard to the specific objectives, financial situation and particular needs of any specific person. Investors may wish to seek advice from an independent financial advisor before investing in any investment or insurance product. Should you choose not to seek such advice, you should consider whether the investment or insurance product in question is suitable for you.